Instructions for Phosphogliv URSO (Glycyrrhizic acid, Ursodiol) 50 capsules 35 + 250 mg
English Product Name
Phosphogliv Urso
Dosage form
Capsules
Description Phosphogliv URSO:
Capsules hard gelatin, No0, white; contents - white or white powder with a cream tint of color.
1 caps.
ursodeoxycholic acid 250 mg
sodium glycyrrhizinate 35 mg
Excipients:
microcrystalline cellulose M 101 - 30.5 mg,
croscarmellose sodium - 6.6 mg,
hyprolose (hydroxypropyl cellulose) - 3.3 mg,
magnesium stearate - 2.8 mg,
silicon dioxide colloidal (aerosil) - 1.8 mg.
Composition of the capsule shell (body and lid):
titanium dioxide (E 171) - 1.92 mg,
gelatin - 94.08 mg.
ten pieces. - Cellular contour packs (5) - cardboard packs.
pharmachologic effect Phosphogliv URSO:
Combined drug.
It has hepatoprotective, choleretic, cholelitolytic, antioxidant, anti-inflammatory action; affects fibrogenesis.
Ursodeoxycholic acid
Bile acid. Reduces the cholesterol content in bile mainly by dispersing cholesterol and forming a liquid crystalline phase. It affects the enterohepatic circulation of bile salts, reducing the reabsorption in the intestine of endogenous more hydrophobic and potentially toxic compounds. In vitro studies have shown that ursodeoxycholic acid has a direct hepatoprotective effect and reduces the hepatotoxicity of hydrophobic bile salts. It affects immunological reactions, reducing the pathological expression of HLA-antigens of class I on hepatocytes and suppressing the production of cytokines and interleukins.
Testimony Phosphogliv URSO:
- Non-alcoholic steatohepatitis,
- alcoholic liver disease,
- chronic hepatitis of various origins,
- biliary reflux gastritis,
- biliary dyskinesia of the biliary tract,
- dissolution of cholesterol stones of the gallbladder,
- primary biliary cirrhosis of the liver in the absence of signs of decompensation,
- primary sclerosing cholangitis.
Dosage, Course and Dosage:
Inwards. The dosage regimen is individual, depending on the indications, the patient's age and the clinical situation.
Use in children
The drug is contraindicated for use in children and adolescents under the age of 12 years
- Nosology Phosphogliv URSO (ICD codes)
- B18
- Chronic viral hepatitis
- K29
- Gastritis and duodenitis
- K70
- Alcoholic liver disease
- K73
- Chronic hepatitis not classified under other headings
- K74.3
- Primary biliary cirrhosis
- K76.0
- Fatty liver (liver degeneration), not classified under other headings
- K80
- Cholelithiasis [cholelithiasis] (including hepatic colic)
- K82.8
- Other advanced diseases of the gallbladder and cystic duct (including dyskinesia)
- K83.0
- Cholangitis